- Boehringer Ingelheim Limited (BIL) made payments to the Department of Health and Social Care (DHSC) under schemes to control NHS spending on branded medicines.
- BIL claimed these payments should reduce the VAT consideration for their pharmaceutical supplies, but HMRC rejected this.
- The First-tier Tribunal initially sided with BIL, but the Upper Tribunal overturned this decision.
- The Upper Tribunal ruled that the payments were not linked closely enough to the supply chain to reduce VAT consideration, as DHSC was not part of the supply chain.
- HMRC’s appeal was allowed, except for a few payments related to medicines supplied directly to DHSC.
Source: taxscape.deloitte.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "United Kingdom"
- UT: Payments to DHSC by Medicine Manufacturer Not VAT Price Reductions; Rebate Mostly Denied
- Court Ruling Redefines VAT Status for Further Education Colleges: Key Impacts and Next Steps
- Tories Urge Three-Year VAT Cut on Energy Bills to Ease Cost of Living Crisis
- Upper Tribunal Rules VAT Not Reducible on BIL’s NHS Pharmaceutical Payments to DHSC
- HMRC Study: Effects of Penalty Reform on VAT Businesses’ Compliance and Perceptions
